Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Rethinking Sales Model, May Try New Approach To Sampling

Executive Summary

Bristol-Myers Squibb is reexamining the role of sales forces to find new ideas for reaching physicians

You may also be interested in...



Bristol Prepares For Life After Pravachol: Support Will Continue Into 2005

Bristol-Myers Squibb will continue to promote Pravachol over the near term despite declining sales for the statin as wholesalers prepare for generic competition in 2006

Bristol Prepares For Life After Pravachol: Support Will Continue Into 2005

Bristol-Myers Squibb will continue to promote Pravachol over the near term despite declining sales for the statin as wholesalers prepare for generic competition in 2006

Primary Care Rx Market Offers Second-Rate Return On Investment – Bristol

Pharmaceutical companies marketing primary care products are unlikely to see a significant return on their investment, Bristol-Myers Squibb CFO Andrew Bonfield declared June 10

Related Content

UsernamePublicRestriction

Register

PS042821

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel